CClinicalTrials.gg
Status unknownNCT02959684STRADAUpdated May 3, 2018

Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France

An observational study in HIV, Hepatitis C and Hepatitis B, sponsored by University Paris 7 - Denis Diderot. Status unknown at 18 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-03.

Sponsored by University Paris 7 - Denis Diderot · Observational

The sponsor has not verified this record recently (last verified May 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
70,000
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the efficacy of a new screening for infectious diseases: tuberculosis, HIV, HBV and HCV, based on risk factors questionnaires (TB screen for tuberculosis and TROD screen for HIV and hepatitis) amongst a population of legal migrants during their mandatory medical check-up. This study aims for a global improvement of screening and care for migrants.

Read the detailed description

In France, the prevalence of infectious diseases such as tuberculosis, HIV/HBV/HCV is high amongst migrants originating from certain countries, hence the official guidelines recommending targeted testing. The rapid testing devices (TROD) give immediate results and reduce missed opportunities. However their use is not yet widespread and migrant populations remain insufficiently tested. Regarding the UNAIDS 90-90-90 goal, France is failing the screening part of the treatment cascade, while 90% of patients are treated and have undetectable viral load. Risk scores based on the best known risk factors for these infections (HIV/HBV/HCV) have previously been developed. They have helped build a pilot of a new unique questionnaire: TROD screen. An electronic survey, called TB screen, was designed to screen for tuberculosis amongst asylum seekers in Switzerland and validated. This survey enables to detect signs of active tuberculosis and may replace the use of pulmonary radiography, thus reducing exposure to X-rays.

It is a prospective multi-centric observational study validating screening tests for HIV/HBV/HCV in two phases:

  • Phase 1: a risk score will be validated, including a qualitative study analyzing its acceptability
  • Phase 2: its performance will be compared with that of a screening targeted based on the country of origin The phase 1 and phase 2 will include respectively 10.000 and 5000 participants.

For tuberculosis, the efficacy of the improved version of TB screen will be compared with a systematic radiography.

Participation to this study will be voluntary and independent from the delivery of a residence permit. Participants will be informed of it and will systematically receive information about prevention of those infectious diseases.

02

Conditions studied

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Migrants undergoing the routine immigration medical visit

Inclusion criteria

  • Migrants undergoing the routine medical visit
  • Giving informed consent (oral consent)

Exclusion criteria

Exclusion Criteria:

  • Asylum seekers
  • Persons not understanding the questionnaire
  • Persons aware of their HIV, HBV or HCV positive status
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
70,000 participants (estimated)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Comparison of the number of HIV, HBV or HCV positive patients identified in both arms of the screening strategy.

    Time frame: 2 years

  2. Number of tuberculosis patients identified through the modified TB screen questionnaire

    Time frame: 2 years

Secondary outcomes

  1. Number of HIV/HBV/HCV patients linked to care after being identified through TROD screen.

    Time frame: 2 years

  2. Predictive value of the questionnaire TROD screen.

    Time frame: 2 years

  3. Predictive value of the questionnaire TB screen.

    Time frame: 2 years

  4. Cost-effectiveness of the TROD screen questionnaire compared with a non-targeted screening, calculated in terms of cost per QALY (quality-adjusted life years) gained through this program

    Time frame: 2 years

06

Study locations

17 of 18 sites recruiting
  • OFII Bordeaux
    Bordeaux, France
    • Frédérique Thonon · Contact
    Recruiting
  • OFII Cergy
    Cergy, France
    • Sabrina Lakhdari · Contact
    Recruiting
  • OFII Clermont-Ferrand
    Clermont-Ferrand, France
    Terminated
  • OFII Grenoble
    Grenoble, France
    • Frédérique Thonon · Contact
    Recruiting
  • OFII Lille
    Lille, France
    • Sabrina Lakhdari · Contact
    Recruiting
  • OFII Lyon
    Lyon, France
    • Frédérique Thonon · Contact
    Recruiting
  • OFII Marseille
    Marseille, France
    • Frédérique Thonon · Contact
    Recruiting
  • OFII Melun
    Melun, France
    • Frédérique Thonon · Contact
    Recruiting
  • OFII Metz
    Metz, France
    • Sabrina Lakhdari · Contact
    Recruiting
  • OFII Montpellier
    Montpellier, France
    • Frédérique Thonon · Contact
    Recruiting
  • OFII Montrouge
    Montrouge, France
    • Frédérique Thonon · Contact
    Recruiting
  • OFII Nantes
    Nantes, France
    • Frédérique Thonon · Contact
    Recruiting
  • OFII Nice
    Nice, France
    • Frédérique Thonon · Contact
    Recruiting
  • OFII Orléans
    Orléans, France
    • Frédérique Thonon · Contact
    Recruiting
  • OFII Reims
    Reims, France
    • Frédérique Thonon · Contact
    Recruiting
  • OFII Rennes
    Rennes, France
    • Frédérique Thonon · Contact
    Recruiting
  • OFII Rouen
    Rouen, France
    • Sabrina Lakhdari · Contact
    Recruiting
  • OFII Toulouse
    Toulouse, France
    • Frédérique Thonon · Contact
    Recruiting
07

References and documents

Publications

  • Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, Warszawski J, Steinmetz J, Coste D, Meyer JF, Leiser S, Giordanella JP, Gueguen R, Desenclos JC. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010 Apr;82(4):546-55. doi: 10.1002/jmv.21734. PubMed 20166185 ↗
  • Schneeberger Geisler S, Helbling P, Zellweger JP, Altpeter ES. Screening for tuberculosis in asylum seekers: comparison of chest radiography with an interview-based system. Int J Tuberc Lung Dis. 2010 Nov;14(11):1388-94. PubMed 20937177 ↗
  • d'Almeida KW, Kierzek G, de Truchis P, Le Vu S, Pateron D, Renaud B, Semaille C, Bousquet V, Simon F, Guillemot D, Lert F, Cremieux AC; Emergency Department HIV-Screening Group. Modest public health impact of nontargeted human immunodeficiency virus screening in 29 emergency departments. Arch Intern Med. 2012 Jan 9;172(1):12-20. doi: 10.1001/archinternmed.2011.535. Epub 2011 Oct 24. PubMed 22025095 ↗
  • d'Almeida KW, Pateron D, Kierzek G, Renaud B, Semaille C, de Truchis P, Simon F, Leblanc J, Lert F, Le Vu S, Cremieux AC. Understanding providers' offering and patients' acceptance of HIV screening in emergency departments: a multilevel analysis. ANRS 95008, Paris, France. PLoS One. 2013 Apr 29;8(4):e62686. doi: 10.1371/journal.pone.0062686. Print 2013. PubMed 23638133 ↗
  • Bottero J, Boyd A, Gozlan J, Carrat F, Nau J, Pauti MD, Rougier H, Girard PM, Lacombe K. Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. Open Forum Infect Dis. 2015 Oct 26;2(4):ofv162. doi: 10.1093/ofid/ofv162. eCollection 2015 Dec. PubMed 26668814 ↗
  • Haukoos JS, Lyons MS, Lindsell CJ, Hopkins E, Bender B, Rothman RE, Hsieh YH, Maclaren LA, Thrun MW, Sasson C, Byyny RL. Derivation and validation of the Denver Human Immunodeficiency Virus (HIV) risk score for targeted HIV screening. Am J Epidemiol. 2012 Apr 15;175(8):838-46. doi: 10.1093/aje/kwr389. Epub 2012 Mar 19. PubMed 22431561 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT02959684
Lead sponsor
University Paris 7 - Denis Diderot
Responsible party
Dr Martin Duracinsky (Dr, University Paris 7 - Denis Diderot) — Principal investigator
First posted
Nov 9, 2016
Start date
Apr 14, 2017
Primary completion
Jul 2018 (estimated)
Completion
Jul 2019 (estimated)
Last update
May 3, 2018

Study contacts

Martin Duracinsky, MD, PhD
Contact
duracinsky.m@gmail.com
+33140275543
Frédérique Thonon, PhD
Contact
studymanager.proqol@gmail.com
+33140275543

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion